Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Blue Wolf Capital Partners in connection with the acquisition of seven manufacturing and development facilities from Recipharm
Mandate

Vinge advises Blue Wolf Capital Partners in connection with the acquisition of seven manufacturing and development facilities from Recipharm

September 03, 2024 M&A Real Estate and Construction Employment and Benefits Commercial Agreements FDI Carve-Outs

Vinge has, together with Kirkland & Ellis, advised Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the healthcare and industrial sectors, in connection with the acquisition of seven manufacturing and development facilities in Sweden, France, and Spain, from Recipharm Group, a contract development and manufacturing organization (“CDMO”) headquartered in Stockholm.

The seven facilities have been a part of Recipharm for over a decade and have focused on the manufacturing and development of oral solid, semi-solid and liquid dosage form pharmaceutical products. The facilities serve over 120 customers around the world and have a strong track record of quality and regulatory compliance. Together these sites are to form a new independent CDMO platform with continued focus on pharmaceutical manufacturing operating under a new corporate name to be announced after the transaction closes.

Vinge’s team consisted of among other Jonas Bergström, Matthias Pannier, Carl Sander, Per Kling and Alexander Rüdén (M&A), Sam Seddigh, Emil Lindwall and Agnes Pigg (Employment), Johan Cederblad, Lina Österberg and Madelene Andersson (Real Estate and Environment) Stojan Arnerstål (Life Science and Regulatory), Mathilda Persson, Fredrika Hjelmberg, Christoffer Nordin, Carla Zachariasson and Elis Allmark (Commercial Contracts and Separation), Daniel Wendelsson, David Olander, Hilda Ivarsson and Hanna Lemne (FDI) and Anna Ekdahl Roos (Transaction Support).

Related

Vinge advises Fortinova Fastigheter AB (publ) on its first SEK 200 million green bond issue

 Vinge has advised Fortinova Fastigheter AB (publ) (“Fortinova”) on the company’s first issue of senior unsecured green bonds in an aggregate principal amount of SEK 200 million, under a framework of up to SEK 600 million. Nordea, acted as sole bookrunner in connection with the bond issue.
September 18, 2026

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

 Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026

Vinge advises HealthCap in conjunction with its investment in AMRA Medical

 HealthCap is investing in AMRA Medical AB, a company that analyses whole-body MRI images to classify and quantify an individual’s muscle and fat tissue throughout the body and places this in relation to human health and disease.
September 15, 2026